PMID- 31264282
OWN - NLM
STAT- MEDLINE
DCOM- 20200911
LR  - 20200911
IS  - 1365-2222 (Electronic)
IS  - 0954-7894 (Linking)
VI  - 49
IP  - 10
DP  - 2019 Oct
TI  - Pragmatic evaluation of inhaled corticosteroid particle size formulations on 
      asthma control.
PG  - 1321-1327
LID - 10.1111/cea.13453 [doi]
AB  - BACKGROUND: Extra-fine particle formulations of inhaled corticosteroid (ICS) are 
      associated with improved lung delivery. OBJECTIVES: A pragmatic study to assess 
      patient-reported outcomes after switching from fine to extra-fine particle ICS in 
      persistent asthma. METHODS: Twenty-four patients (mean age 48 year, FEV(1) 84%, 
      ACQ 1.67) received 4 weeks run-in with a constant dose of fine particle ICS (mean 
      dose 710 microg), followed by switching to an equivalent dose of extra-fine particle 
      hydrofluoroalkane beclomethasone dipropionate (mean dose 355microg). Asthma control 
      questionnaire (ACQ), the primary outcome and mini asthma quality of life 
      questionnaire (mAQLQ) were measured pre- and post-run-in (baseline) and after 
      4 weeks and 8 weeks of switching. RESULTS: Comparing pre- vs post-run-in, there 
      were no differences for ACQ: 1.67 vs 1.65 or AQLQ: 5.08 vs 5.34. There were mean 
      (95%CI) improvements (P < 0.001) from baseline after 8 weeks for ACQ: -0.53 
      (-0.83, -0.23) and AQLQ: 0.69 (0.35, 1.04), which exceeded the minimal clinically 
      important difference (MCID) of 0.5 for both. There were also differences 
      (P < 0.05) in domiciliary symptoms and reliever use. There were no significant 
      changes at 8 weeks in lung function, FeNO or blood eosinophils. CONCLUSIONS: 
      Pragmatic switching from fine to extra-fine particle ICS at half the dose was 
      associated with clinically relevant improvements in asthma control and quality of 
      life, but not lung function or type 2 biomarkers.
CI  - (c) 2019 John Wiley & Sons Ltd.
FAU - Kuo, Chris RuiWen
AU  - Kuo CR
AUID- ORCID: 0000-0001-5954-6620
AD  - Scottish Centre for Respiratory Research, Ninewells Hospital and Medical School, 
      University of Dundee, Dundee, UK.
FAU - Jabbal, Sunny
AU  - Jabbal S
AUID- ORCID: 0000-0002-9604-9807
AD  - Scottish Centre for Respiratory Research, Ninewells Hospital and Medical School, 
      University of Dundee, Dundee, UK.
FAU - Anderson, William
AU  - Anderson W
AD  - Scottish Centre for Respiratory Research, Ninewells Hospital and Medical School, 
      University of Dundee, Dundee, UK.
FAU - Lipworth, Brian J
AU  - Lipworth BJ
AD  - Scottish Centre for Respiratory Research, Ninewells Hospital and Medical School, 
      University of Dundee, Dundee, UK.
LA  - eng
SI  - EudraCT/2012-003923-39
SI  - ClinicalTrials.gov/NCT01894048
PT  - Journal Article
PT  - Pragmatic Clinical Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20190806
PL  - England
TA  - Clin Exp Allergy
JT  - Clinical and experimental allergy : journal of the British Society for Allergy 
      and Clinical Immunology
JID - 8906443
RN  - 0 (Adrenal Cortex Hormones)
SB  - IM
MH  - Administration, Inhalation
MH  - Adolescent
MH  - Adrenal Cortex Hormones/*administration & dosage/adverse effects
MH  - Adult
MH  - Aged
MH  - Asthma/*drug therapy/physiopathology
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Particle Size
MH  - *Quality of Life
MH  - *Surveys and Questionnaires
OTO - NOTNLM
OT  - asthma
OT  - patient reported asthma outcomes
OT  - pharmacology
OT  - quality-of-life
EDAT- 2019/07/03 06:00
MHDA- 2020/09/12 06:00
CRDT- 2019/07/03 06:00
PHST- 2019/02/01 00:00 [received]
PHST- 2019/05/07 00:00 [revised]
PHST- 2019/06/26 00:00 [accepted]
PHST- 2019/07/03 06:00 [pubmed]
PHST- 2020/09/12 06:00 [medline]
PHST- 2019/07/03 06:00 [entrez]
AID - 10.1111/cea.13453 [doi]
PST - ppublish
SO  - Clin Exp Allergy. 2019 Oct;49(10):1321-1327. doi: 10.1111/cea.13453. Epub 2019 
      Aug 6.